Evidence map›Paper›PMID 35271331›Full record

ArticleScience (New York, N.Y.)2022

Protecting the herd with vaccination.

Natalie E Dean, M Elizabeth Halloran

Abstract readComment
PubMed Publisher
In one paragraph

Article in Science (New York, N.Y.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Optimality of Maximal-Effort Vaccination.Bulletin of mathematical biology · 2023
    Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Natalie E DeanDepartment of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, USA.
M Elizabeth HalloranVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Funding

Design and Analysis of Vaccine Trials for Emerging Infectious Disease ThreatsR01AI139761 · NIAID · UNIVERSITY OF FLORIDA · PI DEAN, NATALIE EXNER · 2018 to 2022
$3.6M
NIAID NIH HHS R01 AI139761
6 · The paper itself

Abstract

How much do COVID-19 vaccines reduce transmission? The answer is a moving target.

Indexed as

COVID-19Immunity, HerdCOVID-19 VaccinesHumansSARS-CoV-2VaccinationCOVID-19 Vaccines

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.